BrainsWay Ltd. (NASDAQ:BWAY) Sees Large Increase in Short Interest

BrainsWay Ltd. (NASDAQ:BWAY) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 49,600 shares, a growth of 81.0% from the December 15th total of 27,400 shares. Based on an average daily trading volume, of 76,700 shares, the short-interest ratio is presently 0.6 days.

Analysts Set New Price Targets

BWAY has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of BrainsWay in a report on Monday, December 23rd. Northland Securities raised their target price on BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a report on Thursday, October 3rd.

BrainsWay Stock Up 5.2 %

BWAY stock traded up $0.49 during trading on Tuesday, reaching $9.92. The stock had a trading volume of 90,391 shares, compared to its average volume of 45,988. The company has a market capitalization of $186.62 million, a price-to-earnings ratio of 99.21 and a beta of 1.23. BrainsWay has a one year low of $4.61 and a one year high of $10.98. The company’s 50 day moving average is $9.71 and its two-hundred day moving average is $8.58.

BrainsWay (NASDAQ:BWAY) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. BrainsWay had a return on equity of 3.52% and a net margin of 3.88%. The company had revenue of $10.50 million during the quarter, compared to the consensus estimate of $10.07 million. During the same period last year, the business posted ($0.01) earnings per share. As a group, research analysts predict that BrainsWay will post 0.06 earnings per share for the current fiscal year.

Institutional Trading of BrainsWay

Several hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers grew its stake in shares of BrainsWay by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock worth $110,000 after acquiring an additional 1,695 shares during the period. Good Life Advisors LLC lifted its holdings in BrainsWay by 65.5% during the third quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock valued at $516,000 after purchasing an additional 22,080 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in BrainsWay by 316.3% during the third quarter. JPMorgan Chase & Co. now owns 14,769 shares of the company’s stock worth $136,000 after purchasing an additional 11,221 shares during the period. Institutional investors own 30.11% of the company’s stock.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.